That's up more than 10 percent from 2013 and up from $75 billion five years earlier, according to a new report.» Read More
Jon Najarian, co-founder of OptionMonster.com, breaks down a worrisome trend in the stock market right now.
Intarcia Therapeutics Inc. said it raised $225 million in the latest in a series of financing to support the development of its implantable drug-delivery pump for patients with diabetes.Kurt Graves, Intarcia Therapeutics chairman and CEO, discusses.
Pfizer is the bidder for Sobi, the disease specialist which disclosed that a potential buyer had made an offer, sources said.
Carter Worth, head of technical analysis at Cornerstone Macro, talks U.S. stocks, including biotech, and what to expect in the month of May.
Sales of the novel hepatitis C drugs Sovaldi and Harvoni helped the company top Wall Street estimates.
Biotech is bunking up in Cambridge's hottest zip codes as an affordable way to be in the hotbed of research. Details, with CNBC's Meg Tirrell.
CNCB's Meg Tirrell reports on one of the biotechnology industry's capital cities. 130 life sciences companies occupy Kendall Square in Cambridge, Massachusetts.
Real estate in Kendall Square is exploding, where biotech and big pharma companies are finding homes. Joel Marcus, Alexandria Real Estate CEO, discusses what's driving the real estate boom in the area.
As biotech has boomed over the last few years, so has real estate in Kendall Square in Cambridge, Massachusetts.
David Cordani, Cigna CEO, discusses Cigna's business strategy, the high price of drugs, and Obamacare.
CNBC's Meg Tirrell reports the boom in biotechnology is prompting a hunt for real estate in the Boston area, squeezing rents and forcing vacancy rates to historic lows.
Ariad Pharmaceuticals' CEO will retire this year in a settlement with hedge fund Sarissa Capital, capping months of agitation.
George Scangos, Biogen CEO, discusses progress in clinical trials for Alzheimer's treatments, and the outlook for its multiple sclerosis Tecfidera drug.
The manager of Fidelity Biotech's portfolio is optimistic about the future of biotech as he sees a continuous attempt to innovate.
Rajiv Kaul, Fidelity biotech portfolio manager, discusses long term investing and why he is optimistic about the biotech sector going forward.
Pfizer reported a 4 percent drop in quarterly revenue, while Merck posted earnings that topped expectations.
Celladon said it expected to cut jobs after the company's experimental gene therapy to treat heart failure failed a key trial.
Fred Hassan, Warburg Pincus Partner and Managing Director, discusses the latest pharmaceutical deals making headlines and believes Mylan and Perrigo are the most complementary for a deal.
CNBC's David Faber reports on pharmaceutical acquisitions making headlines including Mylan and Perrigo.
Evan Schoenbach, early stage tech investor at Mosaic Ventures, says there are several great reasons why investment is flowing into Europe right now.
Get the best of CNBC in your inbox